Date:5/5/2010

es and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include (but are not limited to) uncertainties and risks regarding: the effect of the CareFusion spinoff on Cardinal Health; the performance of CareFusion and the proceeds realized from future sales of CareFusion stock; uncertainties due to government health care reform including the recently enacted federal health care reform legislation; competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; disruptions in the supply of medical isotopes for the nuclear pharmacy business; the timing of generic and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement rates for health care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal or administrative proceedings; the effects of disruptions in the financial markets, including uncertainties related to the availability and/or cost of credit on Cardinal Health's customers and vendors; with respect to future dividends, the decision by Cardinal Health's board of directors to declare such dividends, which decision will depend on Cardinal Health's surplus, earnings, cash flows, financial condition and prospects at the time any such action is considered; and conditions in the pharmaceutical market and general economic and market conditions. In addition, Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to t
'/>"/>

SOURCE Cardinal Health, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
2. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
3. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
4. Cardinal Health Completes Enturia Acquisition
5. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
6. AmeriCares Honors Cardinal Health with Power of Partnership Award
7. Cardinal Health Helps Hospitals Save More Than $20 Million In Pharmaceutical Costs; Connect Low-Income Patients With Affordable Medications
8. Cardinal Health Executives to Speak at Two Investor Events in January
9. Cardinal Health Names Carrie Cox to Board of Directors
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health